AQX-1125

DRUG5 trials

Sponsors

Aquinox Pharmaceuticals (Canada) Inc.

Conditions

Atopic DermatitisBladder Pain SyndromeCOPDHealthy VolunteerInterstitial Cystitisbladder pain syndrome Interstitial cystitis

Phase 1

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study

CompletedNCT03478020

Aquinox Pharmaceuticals (Canada) Inc.Healthy Volunteer

Start: 2017-11-22End: 2018-04-05Updated: 2018-06-13

Phase 2

Efficacy and Safety of AQX-1125 in IC/BPS

CompletedNCT01882543

Aquinox Pharmaceuticals (Canada) Inc.Bladder Pain Syndrome, Interstitial Cystitis

Start: 2013-06-30End: 2015-06-30Updated: 2017-09-05

Efficacy and Safety of AQX-1125 in Unstable COPD

CompletedNCT01954628

Aquinox Pharmaceuticals (Canada) Inc.COPD

Start: 2013-10-31End: 2015-12-31Updated: 2017-06-12

Pilot Efficacy and Safety Study of AQX-1125 in Atopic Dermatitis

CompletedNCT02324972

Aquinox Pharmaceuticals (Canada) Inc.Atopic Dermatitis

Start: 2014-12-31End: 2015-12-31Updated: 2018-10-05

Phase 3

The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period

Active, not recruitingNL-OMON45365

Aquinox Pharmaceuticals (Canada) Inc.bladder pain syndrome Interstitial cystitis

Start: 2017-11-30Target: 10Updated: 2024-02-28